Planning and Evaluation

规划与评估

• 批准号: 8335531
• 负责人: MICHAEL V. SEIDEN
• 金额: $ 3.54万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-21 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8335531
• 关键词: Accountability; Address; Architecture; Area; Award; Biomedical Research; Businesses; Cancer Center; Cancer Center Support Grant; Cancer Science; Caring; Chairperson; Clinical; Clinical Investigator; Collaborations; Comprehensive Cancer Center; Data; Decision Support Systems; Development; Diagnosis; Direct Costs; Doctor of Medicine; Education; Education and Outreach; Effectiveness; Elements; Employee; Ensure; Equilibrium; Evaluation; Extramural Activities; Faculty; Fox Chase Cancer Center; Foxes; Funding; Funding Agency; Future; Goals; Grant; Growth; Growth and Development function; Heart; Human Resources; Individual; Information Resources; Institution; Instruction; Integrated Delivery Systems; Investigation; Knowledge; Leadership; Malignant Neoplasms; Marshal; Measures; Medicine; Mind; Mission; NCI-Designated Cancer Center; Nursing Faculty; Performance; Philadelphia; Prevention; Prevention strategy; Process; Production; Program Development; Quality of Care; Recruitment Activity; Research; Research Infrastructure; Resource Development; Resources; Science; Site Visit; Strategic Planning; Translational Research; Update; Vision; Visit; anticancer research; base; cancer research center director; clinical care; improved; instrumentation; meetings; member; operation; programs; success; survivorship; tool

Fox Chase Cancer Center (FCCC) has a well-established strategic management planning process and formally produced five-year strategic and financial plans since 1985. These result in rolling five-year recruitment, resource development, and implementation plans which, after review by the Center's External Advisory Board, are approved by the Center Board of Directors. As part of the change in Center leadership during the current CCSG cycle, a comprehensive strategic planning process was launched under the direction of Associate CCSG Director for Academics J. Robert Beck, Wl.D. This is discussed fully in this section of the grant as well as in the "Overall Description of the Cancer Center" and "Developmental Funds" sections. The plan incorporates Center mission, vision, and values, as well as 13 Strategic Objectives. Targeted recruitment to each of the five CCSG Research Programs and a balance of individual investigation and team science are Critical Success Factors for the two Discovery Objectives in the Plan. No CCSG funds are requested for this planning effort. CCSG funds are requested for two aspects of our evaluation efforts. First, we seek support for our six external advisory boards, five of which provide review and advice to each of our scientific Programs. The sixth, the President's External Advisory Board, is comprised of national leaders in cancer research and NCI designated Cancer Center directors. These External Advisory Boards have been actively involved in our decisions to reconfigure existing or develop new Shared Facilities. They also provide advice on reconfiguration of existing CCSG Programs as well as the balance of team science and individual investigation. The second request is for partial support for our annual daylong Scientific Retreat where members from all five Programs and our clinical investigators meet and discuss opportunities for translational research as well as a broad-range of cancer-related scientific collaborations.

福克斯蔡斯癌症中心（FCCC）有一个完善的战略管理规划过程，并自1985年以来正式制定了五年战略和财务计划。这些导致滚动五年招聘，资源开发和实施计划，经过中心的外部咨询委员会审查，由中心董事会批准。作为中心领导层变动的一部分， 在当前的CCSG周期中，在CCSG学术副主任J. Robert Beck，Wl.D.的指导下，启动了一个全面的战略规划过程。这在补助金的这一部分以及“癌症中心的总体描述”和“发展基金”部分中进行了充分的讨论。该计划包括中心的使命、愿景和价值观，以及13个战略目标。 CCSG五个研究计划中的每一个都有针对性地招募人员，以及个人调查和团队科学的平衡是该计划中两个发现目标的关键成功因素。这项规划工作不需要CCSG资金。 CCSG的资金被要求用于我们评估工作的两个方面。首先，我们为我们的六个外部咨询委员会寻求支持，其中五个为我们的每个科学计划提供审查和建议。第六个是总统的外部顾问委员会，由国家癌症研究和NCI指定的领导人组成。 癌症中心主任。这些外部咨询委员会一直积极参与我们重新配置现有或开发新共享设施的决策。他们还就现有CCSG计划的重新配置以及团队科学和个人调查的平衡提供建议。第二个请求是为我们为期一天的年度科学务虚会提供部分支持，来自所有五个项目的成员和我们的临床研究人员会面并讨论转化研究的机会以及广泛的癌症相关科学合作。